These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2577460)

  • 41. The beta 1 hyperselectivity in beta-blocker treatment.
    Cruickshank JM
    J Cardiovasc Pharmacol; 1995; 25 Suppl 1():S35-46. PubMed ID: 7752668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.
    Niskanen L; Hedner T; Hansson L; Lanke J; Niklason A;
    Diabetes Care; 2001 Dec; 24(12):2091-6. PubMed ID: 11723089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary prevention with beta-blockade in patients with hypertension: review of results and clinical implications.
    Wikstrand J
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S64-75. PubMed ID: 11527139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?
    Ruddy MC
    Curr Hypertens Rep; 2001 Aug; 3(4):289-96. PubMed ID: 11470011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Therapeutic trials in arterial hypertension].
    Gueyffier F
    Rev Prat; 1999 Mar; 49(5):512-8. PubMed ID: 10358401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypertensive cardiovascular disease and the treatment of hypertension in the elderly.
    Pearce KA; Furberg CD
    Curr Opin Nephrol Hypertens; 1994 Mar; 3(2):213-7. PubMed ID: 7842272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension.
    Chen JM; Heran BS; Perez MI; Wright JM
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007185. PubMed ID: 20091622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Office management of hypertension in older persons.
    Aronow WS
    Am J Med; 2011 Jun; 124(6):498-500. PubMed ID: 21605724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of diuretics on morbidity and mortality in the treatment of hypertension.
    Moser M
    Cardiology; 1994; 84 Suppl 2():27-35. PubMed ID: 7954542
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Medical Research Council Hypertension Trial: the smoking patient.
    Dollery C; Brennan PJ
    Am Heart J; 1988 Jan; 115(1 Pt 2):276-81. PubMed ID: 3336995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Palmer CR; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    Lancet; 2000 Jul; 356(9227):366-72. PubMed ID: 10972368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2015 Feb; 33(2):195-211. PubMed ID: 25485720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial therapy of essential hypertension: diuretic or beta blocker?
    Finnerty FA
    J Fam Pract; 1980 Aug; 11(2):199-205. PubMed ID: 6106039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reducing the risk for coronary heart disease and stroke in hypertensives--comments on mechanisms for coronary protection and quality of life.
    Wikstrand J
    J Clin Pharm Ther; 1992 Feb; 17(1):9-29. PubMed ID: 1548319
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.
    J Hypertens; 1985 Aug; 3(4):379-92. PubMed ID: 2864374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic trials of pindolol in hypertension: comparison and combination with other drugs.
    Fanchamps A
    Am Heart J; 1982 Aug; 104(2 Pt 2):388-406. PubMed ID: 6125096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blood pressure reduction and the prevention of stroke.
    MacMahon S
    J Hypertens Suppl; 1991 Dec; 9(7):S7-10. PubMed ID: 1686462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
    Br Med J (Clin Res Ed); 1985 Jul; 291(6488):97-104. PubMed ID: 2861880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.